Published in final edited form as:

Lung Cancer. 2017 April ; 106: 33–36. doi:10.1016/j.lungcan.2017.01.010.

Renal Cyst Formation In Patients Treated With Crizotinib For Non-Small Cell Lung Cancer – Incidence, Radiological Features and Clinical Characteristics

Darragh F Halpenny, MB, BCh, BAO¹, Sinead McEvoy, MB, BCh¹, Angela Li, MD¹, Sumar Hayan, BS¹, Marinela Capanu, PhD³, Junting Zheng, MS³, Gregory Riely, MD², and Michelle S Ginsberg, MD¹

¹Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA, Phone: (212) 639 2000; Fax: (212) 794-4010

²Department of Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA, Phone: (212) 639 2000; Fax: (212) 794-4010

³Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA, Phone: (212) 639 2000; Fax: (212) 794-4010

Abstract

Treatment with the ALK inhibitor crizotinib has been associated with complex renal cyst formation in patients with non-small cell lung cancer (NSCLC). Using patients treated with crizotinib, we aimed to evaluate the incidence of renal cyst formation, to identify risk factors for cyst formation and to provide a radiological description of cyst characteristics. Patients with ALK-positive NSCLC treated with crizotinib were retrospectively identified from an institutional database. Computed tomography (CT) imaging performed prior to and during crizotinib treatment was retrospectively reviewed to assess the size and complexity of pre-existing cysts, new cysts, and enlarging cysts. Demographic data including age, sex, ethnicity, smoking history and length of treatment were also recorded. Data from 60 patients with NSCLC treated with crizotinib at our

Corresponding author: Darragh F Halpenny, MD, Memorial Sloan Kettering Cancer Center, Department of Radiology, 1275 York Avenue, New York, NY 10065, Phone: (212) 639 2000; Fax: (212) 794-4010, halpennd@mskcc.org.

Current address of Sinead McEvoy: Christie NHS Foundation, Department of Radiology, 550 Wilmslow Rd, Manchester M20 4BX, United Kingdom 75 sineadhmccevoy@gmail.com

Current address of Angela Li: Everlight Radiology, 6-10 O'Connell St, Sydney NSW 2000, Australia, angela.eh.li@gmail.com

Disclosures: Darragh F Halpenny – Nothing to disclose

Sinead McEvoy – Nothing to disclose

Greg Riely – Dr. Riely reports grants and personal fees from Novartis, grants and personal fees from Roche, grants from Pfizer, grants from Ariad.

Angela Li – Nothing to disclose

Sumar Hayan BS – Nothing to disclose

Marinela Capanu, PhD – Nothing to disclose

Junting Zheng, MS – Nothing to disclose

Michelle S Ginsberg – Nothing to disclose

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

institution between 6/5/2009 and 7/1/2015 were collected. 57 had CT imaging before and during treatment. Mean length of imaging follow-up was 18 months. 9 (16%) patients had cysts which enlarged or developed de novo during treatment. 2 (4%) patients developed complex renal cysts (1 of these patients also developed complex hepatic cysts). Female gender ($p=0.008$) and the presence of renal cysts on baseline scans ($p=0.044$) were significantly associated with cyst formation or growth. Renal cyst formation or growth occurred in 16% of crizotinib-treated patients. Women and those with pre-existing cysts were at greatest risk. Although the potential causal relationship between crizotinib use and renal cyst formation has yet to be fully defined, it is important for radiologists and clinicians to be aware of this finding.

Keywords

Lung cancer; ALK rearrangement; Crizotinib; Renal cystic lesion

Introduction

Renal cyst formation in patients receiving crizotinib for the treatment of NSCLC was first noted in early-phase trials of this drug [1]. Although the putative role that crizotinib may play in renal cyst formation has not yet been fully defined, crizotinib use has been linked to the growth of pre-existing cysts, and the development of new complex and simple cysts in several patients with NSCLC [1,2]. Cyst formation in this setting has been associated with a longer duration of crizotinib treatment [2], Korean ethnicity [1] and a history of having received previous anticancer medical therapy [2].

Renal cysts are a common and mainly incidental radiological finding [3]. When found on computed tomography (CT) they are frequently classified using the Bosniak classification of renal cysts as either simple or complex [4,5]. The large majority of lesions are either Bosniak category 1 or 2 lesions which are benign and require no follow up. Bosniak category 2F lesions are probably benign, but require follow up, while complex cysts falling into Bosniak category 3 and 4 are frequently surgically managed [5]. Most cysts are simple and considered benign [3], however those classified as complex have an increased risk of malignancy [6].

We aimed to evaluate the incidence of new renal cyst formation or the growth of pre-existing renal cysts, to identify any risk factors for cyst formation, and to provide a radiological description of cysts that form or progress on crizotinib.

Methods

Our institutional review board and privacy board approved this retrospective study. Using institutional databases, we identified crizotinib-treated pL504 patients who had CT or Magnetic Resonance Imaging (MRI) of the kidneys both before and after treatment, which were available for review. Clinical information was collected from the electronic medical record.

CT studies obtained at our institution were performed using 16- and 64-MDCT scanners. The protocol, an abdominopelvic survey, included contrast-enhanced acquisitions during the porto-venous phase (80 seconds following injection) from the diaphragm to the pubic symphysis. 150 mL of contrast material (iohexol, Omnipaque 300, GE Healthcare) was administered at a flow rate of 2.5 mL/s. Reconstructed slice thickness was 5mm for axial images and 2.5mm for coronal and sagittal images. Some CT studies included in the analysis were performed at outside institutions.

Pre-crizotinib CTs and all follow-up CTs while patients were on crizotinib were included for analysis. Images were retrospectively reviewed by 2 radiologists using commercially available PACS software (Centricity, GE Healthcare). A cyst was deemed to have increased in size if a lesion increased by ≥ 4 mm.

Cumulative incidence function of renal cyst formation or growth was estimated from time of crizotinib commencement using Gray's method [7], a class of K-sample tests for comparing the cumulative incidence of a competing risk, using death as a competing risk event. Associations between different risk factors and the cumulative incidence function of renal cyst formation or growth were assessed using Gray's and Fine and Gray methods [8], proportional hazards model for the sub-distribution of a competing risk. Duration of crizotinib treatment (log-transformed) was treated as a continuous time-dependent variable to study its association with risk of cyst formation or growth in a competing risk regression.

Results

Patient characteristics and Imaging findings

Of 60 patients with NSCLC treated with crizotinib between 6/2009 and 7/2015, 57 had pre and post-treatment CT images which included the kidneys in the field of view. 32 (56%) were female. 41 (72%) were never smokers. 46 (81%) were white, 4 (7%) were black and 7 (12%) were Asian. Median age at starting crizotinib treatment was 58 (range 29-87). Mean duration of treatment was 14 months (range 1-67). 7 (12%) patients received crizotinib as first line therapy for lung cancer, while 50 (88%) had received prior chemotherapy for lung cancer.

Twenty-three (38%) patients had baseline renal cysts. Twenty patients had Bosniak 1 lesions, one patient had a Bosniak 2 lesion, and two patients had Bosniak 4 lesions. None of the category 2 or 4 lesions changed during the course of treatment. The mean length of imaging follow-up was 18 months (range 1-73), and the mean number of follow up CTs performed was 7 (range 1-28). Most (46, 81%) patients had baseline CTs with intravenous contrast. The mean number of follow up CTs with contrast was 4 (range 0-16). 43 (75%) had a baseline CT and at least one follow-up CT performed with contrast.

Nine (16%) patients had cysts which enlarged or developed during treatment with crizotinib. Four patients (44%) developed new cysts, while five (56%) developed growth in pre-existing cysts. Eight (89%) were women, mean age was 59 (range 31-81). Two-year cumulative incidence rate (CIR) of cyst change was 19% (95%CI: 7% - 31%). The median length of time on treatment before cyst change was 9.9 months (range 1 -70).

Two patients (4%) developed complex cysts. A 68 year old woman developed bilateral Bosniak 3 cysts measuring up to 53mm, first detectable 10 months after crizotinib treatment, and slowly growing in size and complexity until crizotinib was stopped 13 months later (Figure 1a and b). 2 complex hepatic cysts measuring up to 36mm developed in the same patient. Both the hepatic and renal lesions regressed after crizotinib was stopped. An 81 year old woman developed left sided Bosniak 2F renal cysts measuring up to 50mm 5 months after crizotinib treatment was initiated. The cysts were aspirated, yielding fibrous tissue with acute and chronic inflammation with no bacterial growth or malignant cytology. Two patients developed new Bosniak 1 cysts. The first patient developed a 13mm cyst following 14 months of treatment and the second developed an 8mm cyst following 8 months of treatment. Five patients had Bosniak 1 cysts which enlarged by a mean of 5mm (range 4-9mm) while receiving treatment.

Association between features and renal cyst change

Female sex ($p=0.010$) and the presence of renal cysts on the baseline scan ($p=0.014$) were associated with incidence of renal cyst formation or growth during crizotinib treatment. Of patients who developed cyst change, 8 were women and 6 had baseline renal cysts. A comparison of the clinical and radiological characteristics of patients with and without renal cyst change is provided in Table 1. No association was found between incidence of renal cyst formation or growth and ethnicity ($p=0.154$), having received prior chemotherapy for lung cancer ($p=0.971$), smoking history ($p=0.900$), age ($p=0.97$), having received prior chemotherapy for lung cancer ($p=0.971$) or duration of crizotinib treatment ($p=0.833$).

Discussion

We describe the incidence of renal cyst formation, and the associated radiological and clinical findings, in patients with NSCLC treated with crizotinib. 9/57 patients receiving crizotinib had renal cysts which developed de-novo, or enlarged while on treatment (2-year CIR of 19%). Despite the relatively high incidence of cyst development/growth, just 4% had Bosniak category 2F or greater lesions. Women or patients with pre-existing renal cysts were more likely to demonstrate cyst growth/development.

Renal metastases from lung cancer, although relatively uncommon, are well described [9,10]. Neither of the complex cysts reported here were compatible with renal metastases. In one case the lesion resolved after cessation of crizotinib, and in the other case the lesion was aspirated yielding inflammatory (but not purulent) fluid. The imaging differential diagnosis for a new complex renal cystic lesion also includes a renal abscess, however neither of the cases presented here had clinical evidence of infection. Knowledge of the potential for development of complex renal and hepatic cystic masses in the setting of crizotinib treatment is important, to avoid inadvertently attributing the imaging findings to worsening metastatic disease or abscess formation.

To our knowledge this is the first description of complex hepatic cystic lesions developing in a patient treated with crizotinib. Confidently attributing an isolated new complex cystic hepatic mass to the use of crizotinib could potentially be more difficult given that hepatic metastases are more common than renal metastases [11]. In the patient we report, the hepatic

and renal lesions had the same morphology and developed at the same time, thus simplifying the diagnosis.

We found no association between cyst formation and ethnicity or duration of crizotinib treatment, both of which are clinical factors which have previously been associated with increased risk of cyst formation in this setting [1,2]. A prior study assessing an Asian population demonstrated a higher incidence of both cyst change (22%) and complex cyst formation (13%) than was identified in our population [2]. In addition, a separate study analyzing a more ethnically heterogeneous population found a significant association between Asian (and particularly Korean) ethnicity and the likelihood of new cyst formation during crizotinib treatment [1]. Our study was limited in its ability to assess ethnic differences between Asians and non-Asians given the low number of Asian subjects in our population. The later study, by Schnell et al, reported a comparable overall rate of cyst formation or growth (11%) to that found in our cohort [1].

In conclusion, although no causal relationship has yet been established, a significant minority of patients receiving crizotinib for ALK rearranged NSCLC appear to be at risk for developing complex renal cysts. As genetic profiling of lung cancer and the use of crizotinib become more widespread it is important for radiologists and clinicians to be aware of this potential complication to avoid inappropriately attributing these findings to metastatic disease or abscess formation.

Acknowledgments

This research was funded in part through the NIH/NCI Cancer Center Support Core Grant P30 CA008748.

References

1. Schnell P, Bartlett CH, Solomon BJ, Tassell V, Shaw AT, de Pas T, Lee SH, Lee GK, Tanaka K, Tan W, Tang Y, Wilner KD, Safferman A, Han JY. Complex renal cysts associated with crizotinib treatment. *Cancer Med*. 2015 Jun; 4(6):887–96. [PubMed: 25756473]
2. Lin YT, Wang YF, Yang JC, Yu CJ, Wu SG, Shih JY, Yang PC. Development of renal cysts after crizotinib treatment in advanced ALK-positive non-small-cell lung cancer. *J Thorac Oncol*. 2014 Nov; 9(11):1720–5. [PubMed: 25436806]
3. Carrim ZI, Murchison JT. The prevalence of simple renal and hepatic cysts detected by spiral computed tomography. *Clin Radiol*. 2003 Aug; 58(8):626–9. [PubMed: 12887956]
4. Bosniak MA. The current radiological approach to renal cysts. *Radiology*. 1986; 158:1–10. [PubMed: 3510019]
5. Bosniak MA. The use of the Bosniak classification system for renal cysts and cystic tumors. *J Urol*. 1997; 157:1852–1853. [PubMed: 9112545]
6. Han HH, Choi KH, Oh YT, Yang SC, Han WK. Differential diagnosis of complex renal cysts based on lesion size along with the Bosniak renal cyst classification. *Yonsei Med J*. 2012 Jul 1; 53(4):729–33. [PubMed: 22665338]
7. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing Risk. *Annals of Statistics*. 1988; 16:1141–1154.
8. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. *J Amer Statist Assoc*. 1999; 94:496–509.
9. Derweesh IH, Ismail HR, Magi-Galluzzi C, Hale J, Goldfarb DA. Non-small cell lung carcinoma metastatic to the kidney. *Can J Urol*. 2006 Oct; 13(5):3281–2. [PubMed: 17076953]

10. Ishihara S, Kobayashi S, Yamaha M, Takeuchi T, Kuriyama M, Ban Y, Kawada Y, Takahashi Y, Horie M, Isogai K. Hinyokika Kiyo. Metastatic renal tumor from the lung with regional lymph node involvement: a case report. Hinyokika Kiyo. 1990 Jan; 36(1):51–4. [PubMed: 2408264]
11. Riihimäki M, Hemminki A, Fallah M, Thomsen H, Sundquist K, Sundquist J, Hemminki K. Metastatic sites and survival in lung cancer. Lung Cancer. 2014 Oct; 86(1):78–84. [PubMed: 25130083]

Highlights

- Complex renal cyst formation occurred in 4% of patients treated with crizotinib
- Cyst growth was associated with female sex and the presence of pre-existing cysts
- We provide the 1st description of complex liver cysts in patients receiving crizotinib

Figure 1.
a and b. Axial post contrast CT images of the left kidney in a 68 year old female patient, before crizotinib treatment (Figure 1a) and 10 months after crizotinib treatment (Figure 1b). The post treatment image demonstrates the development of a complex cystic lesion with numerous internal septations, some of which were thickened and had measureable enhancement (Bosniak category 3).

Table 1
Associations between clinical/radiological features and renal cyst change

	Total (%)	2-year CIR of Cyst Change (95%CI)	P value
Sex, n (%)			
Female	32 (56)	0.317 (0.122, 0.513)	0.010
Male	25 (44)	0 (0,0)	
Ethnicity (%)			
White	46 (84)	0.400(0, 0.890)	0.154
Black	4 (7)	0.250 (0, 0.767)	
Asian	5 (9)	0.152 (0.024, 0.280)	
Renal cyst on baseline imaging (%)			
Yes	24 (42)	0.370 (0.120, 0.621)	0.014
No	33 (58)	0.078 (0, 0.187)	
Smoking History (%)			
Yes	16 (28)	0.200 (0, 0.425)	0.900
No	41 (72)	0.171 (0.029, 0.313)	
Received chemotherapy prior to crizotinib (%)			
Yes	50 (88)	0.180 (0.056, 0.304)	0.971
No	7 (12)	0.333 (0, 0.987)	
HR of Cyst Change (95%CI)			
Median Age(Range), years	58 (29, 87)	1.00 (0.94, 1.06)	0.970
Median duration of crizotinib treatment before cyst change (range), months	9.9 (1-70)	1.04 (0.70, 1.56)	0.833

CIR = Cumulative incidence rate; HR = Hazard ratio; CI = Confidence interval.